Metastatic Pancreatic Ductal Adenocarcinoma
FDA Accepts sNDA for NALIRIFOX as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
SG Tylor
Source: Ipsen Pharma The FDA has accepted a supplemental new drug application (sNDA) for the combination of liposomal irinotecan, 5-fluorouracil, ...
ASCO 2023: How NALIRIFOX Can Extend the Lives of Patients with Metastatic Pancreatic Cancer
SG Tylor
ABSTRACT NUMBER – 4006 The combination of liposomal irinotecan with 5-fluorouracil/leucovorin (5-FU/LV) has already received approval for treating metastatic pancreatic ...
